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PRP16
RESOURCE UTILIZATION (HOSPITAL AND
PHYSICIAN COST/VISITS) AFTER
INTRODUCTION OF THE NEW TREATMENT
GUIDELINES IN ASTHMA (1997)
Mehta R1, Cady P2
1Idaho State University, Salt Lake City, UT, USA; 2Idaho State
University, Pocatello, ID, USA
OBJECTIVE: To evaluate the resource utilization after
introduction of new treatment guidelines in Asthma
(1997). METHODS: Paid claims for inpatient, outpatient
and pharmacy services during the period 1994 through
2000 were collected. New treatment guidelines solicited
use of anti-inﬂammatory medications for patients using
more than 1 canister of beta-inhaler /month. Chronic
users (CUs): using more than 10 canisters of beta-
inhaler/year. Patients were further categorized: CHBYAi
(CUs, using some anti-inﬂammatory medication; “appro-
priate therapy”) and CHBNAi (CUs not using any anti-
inﬂammatory medication). Univariate analyses for
continuous variables was performed using Wilcoxon-
Rank Sum test and multivariate logistic regression was
performed to predict the probability of being on appro-
priate therapy. RESULTS: A total of 1293 patients were
using more than 10 canisters of beta-inhalers, of which
923 (71%) were on appropriate therapy. The CHBNAi,
for year 1998, had signiﬁcantly fewer asthma-related
physician visits (52.6 Vs 81.0) and costs (59.9 Vs 111.8);
asthma-related hospital visits (78.0 Vs 90.0) and costs
(90.5 Vs 112.3) compared to CHBYAi (p < 0.001); 
statistically signiﬁcant and consistent across the years.
Adjusted r-square for multivariate logistic regression
across the years: 15.1% to 28.9%. Total asthma-related
physician visits and age (1998) were signiﬁcantly associ-
ated with the odds of being on appropriate therapy across
all the years. For example, in 1998, each patient, with
asthma-related physician visit was twice as likely (90%
CI: 1.410–2.843), and each unit increase in age was 0.981
times likely (90% CI: 0.965–0.998); to be on appropri-
ate therapy. CONCLUSION: Per the guidelines, we
would have expected a higher health care utilization
(visits & cost) for the CHBNAi group but we could not
conclude this and it could be related to factors such as
severity of illness.
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THE AVERAGE COSTS OF THE TREATMENT OF
ASTHMA EXACERBATIONS IN IN-PATIENT
CARE AND HOSPITAL EMERGENCY ROOM IN
POLAND
Plisko R1,Wcislo J1, Landa K1, Glogowski CA2,
Gierczynski JM2
1HTA Consulting, Krakow, Malopolska, Poland;
2GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland
OBJECTIVES: The objective of this analysis was to inves-
tigate direct cost of asthma exacerbations in Poland from
the perspective of the payer and the service provider.
METHODS: To examine the current practice of asthma
exacerbations treatment a survey in 4 hospitals was per-
formed. The hospitals were chosen on the basis of differ-
ent ﬁxed cost class. In those hospitals data concerning 
the cost of asthma exacerbations treatment were col-
lected. According to current practice severe asthma exac-
erbations were treated in-patiently and mild or moderate
asthma exacerbations were treated in hospital emergency
rooms (usual stay for one day). The following costs were
calculated for inpatient care (severe exacerbations): hos-
pital stay, pharmaceuticals, personnel, and diagnostic
procedures. An assumption that average hospital admis-
sion took 10 days was made. On the basis of collected
data the pharmaceuticals utilization per 10-day hospital
stay was assessed. For the purpose of this assessment the
decision tree was formulated: the proportions expressing
probabilities of patients receiving speciﬁc drug therapy,
duration of drug therapy and route of the drug adminis-
tration were calculated. For asthma exacerbations treated
in hospital emergency room similar cost groups were
included. Sensitivity analysis was performed. RESULTS:
The average costs per patient care were estimated: hospi-
tal stay 200 PLN (€50) 1 day; drug utilization 435.3 PLN
(€110); 10 day personnel 66.39 PLN (€17); 1 day diag-
nostic procedures 91.4 PLN (€23) per hospital admission.
The average cost of inpatient treated (10 days) asthma
exacerbation was estimated at 3190.61 (€798) per one
patient. The average cost of asthma hospital emergency
room care was estimated at 172.60 PLN (€40) per
patient/day. CONCLUSION: This cost analysis of asthma
exacerbations treatment is one of the ﬁrst performed in
Poland. Further analysis should include more centers to
allow conﬁdence interval estimation.
PRP18
PHARMACOECONOMIC COMPARISON
BETWEEN TWO DRUG STRATEGIES OF
TREATMENT OF RECURRENT ACUTE
RHINOPHARYNGITIS IN 18-MONTH-OLD TO 
4-YEAR-OLD CHILDREN: HOMEOPATHY AND
ANTIBIOTICS
Trichard M1, Chaufferin G1, Nicoloyannis N2
1Laboratoires BOIRON, Sainte-Foy-Lès-Lyon, France;
2Université Lumière Lyon 2, Bron, France
OBJECTIVES: To compare “homeopathic drugs” strat-
egy (H) with “antibiotic drugs” strategy (A) for treating
recurrent acute rhinopharyngitis in France, in terms 
of effectiveness, quality of life, and costs. METHODS:
Effectiveness, quality of life, and costs were derived from
a 6-month pragmatic prospective study including 499
“children aged between 18 months and 4 years, who
experienced at least 5 bouts of rhinopharyngitis in 1999,
and who consulted a homeopathic or non-homeopathic
GP for the ﬁrst time in 2000 either for preventive treat-
ment or for a current bout”. Strategy H included 241 chil-
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dren that received at least 1 homeopathic drug and no
antibiotics, and strategy A 190 children that received at
least 1 antibiotic and no homeopathic drugs. In both
strategies, other drugs could have been prescribed.
Medical effectiveness was assessed by measuring the
number of bouts of acute rhinopharyngitis, the number
of complications, and the quality of family life using the
Par-Ent-Qol© scale. Direct medical costs (medical visits,
medication, additional tests) and indirect costs (sick-
leaves) were assessed from the national health insurance
system viewpoint, using public prices and French Social
Security tariffs. We checked the comparability of patient
population and performed appropriate statistical tests:
Chi-Square test for qualitative variables, and Student,
Mann-Whitney, Kolmogorov-Smirnov tests for quantita-
tive variables. RESULTS: The “homeopathic drugs”
strategy produced signiﬁcantly better results in terms of
medical effectiveness (number of bouts: 2.71 vs 3.97,
number of complications: 1.25 vs 1.95) and quality of life
(global score: 21.38 vs 30.43), for signiﬁcantly lower
direct medical costs reimbursed by the national health
insurance system (88€ vs 99€) and fewer number of sick-
leaves (23 vs 60). CONCLUSION: Homeopathic drugs
could constitute a cost-effective alternative to antibiotics
for treating rhinopharyngitis, and so could provide an
answer to public health and economic problems posed by
the inappropriate use of these drugs in this disease in
France.
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ASTHMA HEALTH CARE EXPENDITURE:
THE ROLE OF CAPITATION AND MANAGED
CARE
Nurmagambetov T,Atherly A,Williams SG, Redd SC
Centers for Disease Control and Prevention, Atlanta, GA,
USA
OBJECTIVES: The objective of this study was to inves-
tigate the effect of capitation on the inpatient and out-
patient expenditures by private health plans for asthma
treatment. METHODS: Data were drawn from the
MEDSTAT Group’s MarketScan database, which has
health care claims data from large employment-based
health insurers. The sample includes 106,943 patients
enrolled in 1999 in one of 5 different types of health
plans: a Health Maintenance Organization (HMO), a
capitated Point-of-Service plan (CPOS), a non-capitated
Point-of-Service plan (NCPOS), a Preferred Provider
Organization (PPO), and a traditional comprehensive
indemnity plan (COMP). The ﬁrst two plans are capi-
tated, and the last three are non-capitated, or fee-for-
service plans. We compared the mean payment between
capitated and non-capitated systems for outpatient and
inpatient care by using t-test for a mean. RESULTS: Cap-
itated plans had signiﬁcantly smaller payments per visit
for outpatient claims ($56 for CPOS and $59 for HMO)
relative to non-capitated COMP ($67), PPO ($71) and
NCPOS ($72) plans (p-value < 0.01). Similarly, mean
payment for each hospitalization under HMO ($3748)
and CPOS ($3783) plans was also signiﬁcantly lower
than under NCPOS ($4139), COMP ($4746), and PPO
($4890) plans (p-value < 0.01). This trend held for all
subgroups, with hospitalization for women being more
costly than for men, $4244 versus $3397 in average for
capitated (p-value < 0.01) and $5090 versus $4204 in
average for non-capitated plans (p-value < 0.01), and for
all age cohorts. CONCLUSION: The mean payment for
outpatient visits and for hospitalizations for asthma
patients in capitated health plans were signiﬁcantly lower
than for non-capitated plans, and these savings in
payment were especially apparent for the case of out-
patient care. Further studies are necessary to determine 
if these “savings” are consistent with quality asthma 
outcomes.
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IMPROVING PHARMACEUTICAL CARE BY THE
PROCUREMENT OF PALIVIZUMAB THROUGH
SPECIALTY DISTRIBUTION
Walker CL, Howell-Smith D, Saba S, Pena A
Humana Inc, Louisville, KY, USA
OBJECTIVES: Audience participants will: 1) understand
the beneﬁts associated with a health plan establishing a
contract with a specialty distributor for the cost-effective
procurement of an expensive injectable; 2) evaluate the
challenges to establishing a contract with a specialty
provider and investigate the steps necessary to foster a
smooth transition for the health plan; and 3) learn about
palivizumab and its prudent use in infants who are at risk
for Respiratory Syncytial Virus (RSV). METHODS:
Due to the high cost of palivizumab, pediatricians were
obtaining referrals for babies to receive monthly
palivizumab injections through an outpatient hospital
setting. The health plans’ cost for hospital administration
was $5225 per palivizumab injection. As a result, the
health plan established a contract with a specialty
injectable provider that supplied the drug at a discount
off average wholesale price (AWP). The drug was then
sent by the specialty distributor to either the physicians’
ofﬁce or the parents’ home for administration. RESULTS:
Through this initiative a cost savings of $3675 per injec-
tion resulted. A total of ﬁfteen at risk infants received
injections during the months of November through April
2001, none of which required hospitalization during 
the Respiratory Syncytial Virus (RSV) season. The health
plan experienced a total cost avoidance of over $180,000
and had the potential to save over $300,000 if all 15
infants were identiﬁed at the beginning of RSV season
(October). CONCLUSION: Establishing a contract with
a specialty distributor can prove to be cost effective for
health plans with large member populations. It is advan-
tageous for the health plan to pursue specialty providers
for the procurement of specialty injectables like
palivizumab, and at the same time provide quality patient
care.
